Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. CTSO.NASDAQ

Cytosorbents Crp (CTSO NASDAQ) stock market data APIs

$0.99 -0.04(-3.9%) as of July 26, 2024
Price chart is built with Anychart

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Cytosorbents Crp Financial Data Overview

1.03
0.99
-
1.04
0.9825
0.7-3.7305
56 434 K
54 306 K
36 686 K
0.575
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CTSO',
Type: 'Common Stock',
Name: 'Cytosorbents Crp',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000C3P8V0',
ISIN: NULL,
CUSIP: NULL,
CIK: '1175151',
EmployerIdNumber: '98-0373793',
FiscalYearEnd: 'December',
IPODate: '2013-11-07',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Medical Devices',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Cytosorbents Crp Fundamental Data is available in our Financial Data APIs

  • Net Revenue 36 686 K
  • EBITDA -25 706 084
  • Earnings Per Share -0.58
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Cytosorbents Crp Earnings via APIs

  • Latest Release 2024-07-30
  • EPS/Forecast -0.09

Get Cytosorbents Crp End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Cytosorbents Crp latest news via APIs

Cytosorbents Corporation (NASDAQ:CTSO) Q3 2023 Earnings Call Transcript

Cytosorbents Corporation (NASDAQ:CTSO) Q3 2023 Earnings Call Transcript November 9, 2023 Cytosorbents Corporation misses on earnings expectations. Reported EPS is $-0.20718 EPS, expectations were $-0...

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery us...
  • BLOOD PURIFICATION
  • BRILINTA
  • CYTOSORB
  • CYTOSORBENTS
  • EARNINGS
  • EARNINGS RELEASES AND OPERATING RESULTS
  • FINANCIAL RESULTS
  • MEDICAL DEVICE
  • NASDAQ:CTSO
  • Q3_2023
  • STAR-T
  • TICAGRELOR
  • WEBCAST
Do you have any questions?
support@eodhistoricaldata.com